[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Cardiol Therapeutics (CRDL)

Cardiol Therapeutics (CRDL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 116,397
  • Shares Outstanding, K 115,245
  • Annual Sales, $ 0 K
  • Annual Income, $ -24,200 K
  • EBIT $ -23 M
  • EBITDA $ -23 M
  • 60-Month Beta 0.74
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 6.29

Options Overview Details

View History
  • Implied Volatility 565.84% (+360.11%)
  • Historical Volatility 36.65%
  • IV Percentile 86%
  • IV Rank 46.29%
  • IV High 1,171.62% on 10/14/25
  • IV Low 43.77% on 03/16/26
  • Expected Move (DTE 6) 0.0000 (0.00%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 20
  • Volume Avg (30-Day) 66
  • Put/Call OI Ratio 0.01
  • Today's Open Interest 1,748
  • Open Int (30-Day) 2,714
  • Expected Range 1.0100 to 1.0100

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.08
  • Number of Estimates 2
  • High Estimate $-0.06
  • Low Estimate $-0.09
  • Prior Year $-0.07
  • Growth Rate Est. (year over year) -14.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.9563 +5.62%
on 07/10/26
1.1050 -8.60%
on 07/06/26
-0.0400 (-3.81%)
since 06/10/26
3-Month
0.9563 +5.62%
on 07/10/26
1.7100 -40.94%
on 04/22/26
-0.3700 (-26.81%)
since 04/10/26
52-Week
0.8800 +14.77%
on 12/01/25
1.7100 -40.94%
on 04/22/26
-0.3600 (-26.28%)
since 07/10/25

Most Recent Stories

More News
Cardiol Therapeutics to Participate in Fireside Chat at B. Riley Securities Mind, Muscle & Vision Summit

TORONTO , July 9, 2026 /PRNewswire/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (" Cardiol " or the " Company "), a late-stage life sciences company advancing anti-inflammatory...

CRDL.TO : 1.44 (-1.37%)
CRDL : 1.0100 (+1.81%)
Cardiol Therapeutics Reports Results of 2026 Annual General Meeting of Shareholders

TORONTO , June 25, 2026 /PRNewswire/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic...

CRDL.TO : 1.44 (-1.37%)
CRDL : 1.0100 (+1.81%)
Cardiol Therapeutics Reports Results of 2026 Annual General Meeting of Shareholders

TORONTO , June 25, 2026 /CNW/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic...

CRDL.TO : 1.44 (-1.37%)
CRDL : 1.0100 (+1.81%)
Cardiol Therapeutics to Webcast Virtual Annual General Meeting of Shareholders on June 24th at 4:30 p.m. EDT

TORONTO , June 23, 2026 /PRNewswire/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic...

CRDL.TO : 1.44 (-1.37%)
CRDL : 1.0100 (+1.81%)
Cardiol Therapeutics to Participate in Fireside Chat at H.C. Wainwright 4th Annual BioConnect Investor Conference at the NASDAQ

TORONTO , May 14, 2026 /PRNewswire/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (" Cardiol " or the " Company "), a late-stage life sciences company advancing anti-inflammatory...

CRDL.TO : 1.44 (-1.37%)
CRDL : 1.0100 (+1.81%)
Cardiol Therapeutics' Phase II MAvERIC Results Accepted for Publication in the Journal of the American Heart Association

TORONTO, ON , May 7, 2026 /CNW/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic...

CRDL.TO : 1.44 (-1.37%)
CRDL : 1.0100 (+1.81%)
Cardiol Therapeutics' Phase II MAvERIC Results Accepted for Publication in the Journal of the American Heart Association

TORONTO, ON , May 7, 2026 /PRNewswire/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic...

CRDL.TO : 1.44 (-1.37%)
CRDL : 1.0100 (+1.81%)
Cardiol Therapeutics Expands U.S. MAVERIC Phase III Trial Network to Address Growing Interest in the Pivotal Program

TORONTO , April 28, 2026 /CNW/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (" Cardiol " or the " Company "), a late-stage life sciences company advancing anti-inflammatory and...

CRDL.TO : 1.44 (-1.37%)
CRDL : 1.0100 (+1.81%)
Cardiol Therapeutics Expands U.S. MAVERIC Phase III Trial Network to Address Growing Interest in the Pivotal Program

TORONTO , April 28, 2026 /PRNewswire/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (" Cardiol " or the " Company "), a late-stage life sciences company advancing anti-inflammatory...

CRDL.TO : 1.44 (-1.37%)
CRDL : 1.0100 (+1.81%)
Cardiol Therapeutics to Highlight MAVERIC Phase III Trial and Recently Published ARCHER Results in Live Interview with Barchart

Toronto, Ontario--(Newsfile Corp. - April 14, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the development...

CRDL.TO : 1.44 (-1.37%)
CRDL : 1.0100 (+1.81%)

Business Summary

Cardiol Therapeutics Inc. is a clinical-stage biotechnology company. It focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease. The company's lead product consist CardiolRx(TM). Cardiol Therapeutics Inc. is based in Oakville, ON.

See More

Key Turning Points

3rd Resistance Point 1.1149
2nd Resistance Point 1.0725
1st Resistance Point 1.0412
Last Price 1.0100
1st Support Level 0.9675
2nd Support Level 0.9251
3rd Support Level 0.8938

See More

52-Week High 1.7100
Fibonacci 61.8% 1.3929
Fibonacci 50% 1.2950
Fibonacci 38.2% 1.1971
Last Price 1.0100
52-Week Low 0.8800

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.